Clay Siegall, Ph.D., co-founder and CEO of Seattle Genetics is now a member of Mirna Therapeutics’ Board of Directors. Texas-based Mirna Therapeutics is a biotechnology-based company that focuses on cancer research, a field in which Dr. Siegall has extensive experience. Mirna’s CEO hopes for Dr. Seigall’s insight regarding iRNA-targeting therapeutics, Mirna’s priority at the moment. Dr. Seigall is a board member of Ultragenyx and Alder BioPharmaceuticals as well.
Under Dr. Siegall’s leadership, Seattle Genetics has put an emphasis on fulfilling cancer patient’s unmet needs. ADCETRIS, the company’s first commercial product, was approved in 2011 and is now available in 64 countries. There are signs that the drug can be used to fight other diseases in addition to cancer. Clay Siegall has the primary responsibility for raising capital for Seattle Genetics; thus far, he has secured over $675 million, both through Seattle Genetic’s initial public offering and private financing deals.
In May of 2016, Dr. Seigall said that his company is currently developing twelve new drugs. One, dubbed 33A, will go into the third phase of clinical trials shortly. The Bothell-based firm expected to hire 100 additional employees each year for the next five years in order develop, test and bring to market new cancer-fighting drugs. Seattle Genetics is also looking at new building to lease since Dr. Seigall notes that “We’re busting at the seams.”
After receiving his Ph.D. in Genetics from George Washington University, and prior to co-founding Seattle Genetics, Dr. Seigall worked at the Bristol-Myers
Squibb Pharmaceutical Research Institute, the National Cancer Institute and the
National Institutes of Health.